Currently, the main focus in T2DM treatment is the prevention and management of cardiovascular disease (CVD), heart failure (HF) and chronic kidney disease (CKD).3 While glycaemic control remains essential, sodium–glucose-transporter-2 (SGLT2) inhibitors or glucagon-like peptide-1 (GLP-1) agonists are increasingly gaining traction due to their beneficial risk-benefit profile. This evidence concerns the gene GCG and chronic kidney disease.